The European Experience with Docetaxel in the Treatment of Early-Stage Breast Cancer
References (17)
- et al.
Evaluation of microtubule associated parameters as predictive markers for advanced breast cancer patients treated with docetaxel
Eur J Cancer
(2001) - et al.
Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
Am J Pathol
(2000) - et al.
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. The 304 Study Group
J Clin Oncol
(1999) - et al.
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group
J Clin Oncol
(1999) - et al.
A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC
Proc Am Soc Clin Oncol
(1999) - et al.
A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (Pts) with metastatic breast cancer (MBC)
Proc Am Soc Clin Oncol
(2001) - et al.
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
Nat Med
(1996) - et al.
Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment
Clin Cancer Res
(1998)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2002 Elsevier Inc. All rights reserved.